Lupin launches Clobazam tablets

Pharma major Lupin informed bourses about its launch of Clobazam Tablets, 10 mg and 20 mg. The company had received approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Clobazam Tablets, 10 mg and 20 mg is the generic version of Lundbeck Pharma's Onfi tablets, 10 mg and 20 mg. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Clobazam Tablets, 10 mg and 20 mg, had an annual sales of approximately US$479 million in the US (IQVIA MAT March 2019).

Lupin is a pharmaceutical company involved in developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. It is the 8th largest generics pharmaceutical company in terms of revenues. The company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT December 2018). 2.9

In Friday’s intraday trade, the stock of Lupin dipped nearly 3 per cent to touch day low of Rs. 838.40 apiece. At 14.48 hours the stock was trading at 838.4 price, down by 2.9 per cent.